Express Healthcare
Home  »  News  »  Who is ideal for antibody cocktail therapy?

Who is ideal for antibody cocktail therapy?

0 54
Read Article

COVID-19 has been a nightmare not only for India but the entire world. But, the good news is antibody cocktail therapy has been touted to be safe in the successful treatment of Covid-19 when it comes to mild to moderately infected patients. Dr Prashant Borade, Head-Critical Care, Global Hospital Mumbai explains about who can opt for this therapy

Antibody cocktail therapy has received a green signal for the treatment of COVID-19. This therapy is given in a combination of two monoclonal antibodies: Casirivimab and Imdevimab which are human immunoglobulin G-1 (IgG1) monoclonal antibodies that act against SARS-CoV-2 virus causing COVID-19 spike protein. The antibody cocktail blocks the attachment of the virus and doesn’t allow it to enter into the human cell. The antibody cocktail is to be administered for the management of patients exhibiting mild to moderate symptoms and having greater chances of severe COVID-19 disease. This therapy is miraculous and lowers the chances of hospitalisation, and aids quick recovery in COVID patients.

Who is ideal for this therapy?

  • COVID-19 patients showcasing mild to moderate symptoms when to comes to adults and children above 12, and weighing around 40 kg who are tested COVID positive, and who are at high risk of developing severe COVID infection and/or hospitalisation simultaneously don’t require oxygen can opt for this therapy
  • Older age group above 60 years
  • Those with hypertension or cardiovascular disease or chronic obstructive pulmonary disease/another chronic respiratory disease
  • Those with congenital or acquired heart disease/ sickle cell disease/ neurodevelopmental disorders like cerebral palsy or gastrostomy or tracheostomy or asthma, or another chronic respiratory disease
  • Diabetes mellitus
  • Obese people
  • Chronic kidney disease
  • Those with cancer, sickle cell anemia, organ transplantation, thalassemia, HIV, or immune deficiencies can go for it
  • Currently on immunosuppressive treatment
  • Hypertension
  • Asthma

Who is not suitable for it?

Casirivimab and Imdevimab cannot be used in the ones who require oxygen therapy due to COVID-19, hospitalised due to COVID-19.

Patients treated with this therapy need to continue to self-isolate and take precautions like hand sanitisation, masking, and social distancing.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
The Radiology Conclave : Embrace the new normal
Register Now